About MingMed
MingMed Biotechnology Co., Ltd. is a PRC-based, clinical-stage biotech company dedicated to the in-house discovery and development of novel, first-in-class drugs addressing global unmet medical needs. Its pipeline spans four therapeutic areas: ophthalmic drugs, recombinant botulinum toxin, immuno-oncology drugs, and pet immune drugs, with most candidates at clinical stage. The company is backed by venture capital and is planning a Hong Kong IPO listing.
Company details
Funding
Total raised
$243.7M
Last stage
Series A
Investors
Founders
Zhang Yan
CEO and founder of MingMed Biotechnology, a Guangzhou-based clinical-stage biotech focused on first-in-class drug development in ophthalmology, oncology, and aesthetics.
Mingguo Huang
Co-founder of MingMed Biotechnology, founded in 2019.
Xuebin Liao
Co-founder of MingMed Biotechnology, founded in 2019.
Yan Zhang
Co-founder and CEO of MingMed Biotechnology; leads the company's drug R&D strategy and has publicly represented the company in fundraising and IPO discussions.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.